Please use this identifier to cite or link to this item:
https://ir.iimcal.ac.in:8443/jspui/handle/123456789/4716| Title: | Covid-19 and Vaccine Equity: Does a patent waiver matter? |
| Authors: | Unni, V.K. Forbes India |
| Keywords: | Covid-19 Trade Related Aspects of Intellectual Property Rights TRIPS Intellectual Property Covishield Sputnik V mRNA |
| Issue Date: | 20-May-2021 |
| Publisher: | Forbes India |
| Abstract: | While a patent waiver may be good news in the long-term, it may not translate into any meaningful gains for India, professor of public policy and management group, IIM Calcutta writes, adding vaccine equity may be an elusive dream |
| Description: | Source: News: Online: Forbes India Dated: 20-05-2021 |
| URI: | https://www.forbesindia.com/article/iim-calcutta/covid19-and-vaccine-equity-does-a-patent-waiver-matter/68039/1#:~:text=The%20answer%20is%20no.,shortage%20and%20inadequate%20production%20facilities https://ir.iimcal.ac.in:8443/jspui/handle/123456789/4716 |
| Appears in Collections: | IIMC Stakeholders |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| ppm-11.pdf | Covid-19 and Vaccine Equity: Does a patent waiver matter? | 367.18 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.